UCSF

UC San Francisco Previously Published Works

Title

Amantadine-Associated Bullous Pemphigoid.

Permalink

<https://escholarship.org/uc/item/9f12j1r4>

Journal

Journal of clinical psychopharmacology, 38(4)

ISSN

0271-0749

Authors

Hoffer, Sarah
Hategan, Ana
Bourgeois, James A

Publication Date

2018-08-01

DOI

10.1097/jcp.0000000000000907

Peer reviewed

ARTICLE COVERSHEET
LWW_CONDENSED(7.75X10.75)
SERVER-BASED

Article : JCP50577

Creator : dpc_lww

Date : Wednesday May 30th 2018

Time : 08:33:47

Number of Pages (including this page) : 4

Amantadine-Associated Bullous Pemphigoid

To the Editors:

Bullous pemphigoid (BP) is an autoimmune dermatological condition characterized by subepidermal blistering.¹ Triggers of BP include trauma, radiation, burns, and vaccines.² It is also associated with several medications and neurologic disorders; for example, an increased incidence of BP in patients with Parkinson disease (PD) has been noted.^{2–4} However, the relationship between BP and antiparkinsonian drugs is less well-defined. Herein we present a patient whose BP may have been precipitated by amantadine use.

CASE REPORT

Mr D, a 77-year-old male, was admitted to inpatient psychiatry for depressive symptoms. He provided written informed consent for publication of this case report. His past medical history included major depressive disorder, a penetrating wound due to a suicide attempt requiring laparotomy and colectomy, type 2 diabetes mellitus, dyslipidemia, hypertension, and recurrent falls. He was noted to have parkinsonian symptoms at the time of admission. He also had a 4-year history of BP triggered by furosemide, confirmed by histopathology examination, and treated with systemic corticosteroids and mycophenolate mofetil. Medications upon admission included

[F1] citalopram (20 mg/d), mirtazapine (30 mg qhs), quetiapine (75 mg qhs), olanzapine (2.5 mg/d), metformin (1000 mg/d), ramipril (2.5 mg/d), rosuvastatin (20 mg/d), vitamin D (2000 units/d), and mycophenolate mofetil

(1000 mg bid). Mycophenolate mofetil was discontinued upon admission because there had been no recurrence of BP-related skin lesions over the previous 4 years and because it had been associated with depressive disorder in published literature.⁵ Quetiapine and olanzapine were tapered and discontinued, but it did not improve his parkinsonism.

During his admission, Mr D was eventually diagnosed with PD. One hundred milligrams of amantadine daily was started and optimized to 100 mg 3 times a day. This significantly reduced his parkinsonian symptoms. However, by week 2 of amantadine use, he began to develop urticarial areas in his distal lower extremities. This progressed into bullae, particularly on the right foot. It then involved the upper extremities, moving distal to proximal and affecting the medial aspects of his arm and forearm. He was assessed by the internal medicine service, and they initiated treatment with triamcinolone, but his rash progressed to his inner thighs and the dorsum of his feet bilaterally, predominantly on the right side. A 7-day trial of cephalexin for presumed cellulitis did not improve the lesions. A provisional diagnosis of BP recurrence was made. Given that symptoms began after introduction of amantadine, it was hypothesized that this drug may have triggered the BP episode; the medication was discontinued at week 4 of use. This halted progression of the rash; by week 5, Mr D had no new lesions and the old ones were mostly denuded. Figure 1 shows various healing stages of his lesions. He was discharged from hospital with outpatient follow-up arranged with dermatology. At 6-month psychiatric follow-up, his BP had remained in clinical

remission, while he was not rechallenged with any antiparkinsonian medication.

DISCUSSION

This case is remarkable because our patient developed BP lesions after being started on amantadine. We propose that amantadine may trigger BP, which could potentially explain the increased incidence of BP in PD patients. Although our patient had a preexisting diagnosis of BP, an increased incidence of newly diagnosed BP in patients with an established diagnosis of PD has been noted.⁴ If amantadine is truly a BP trigger, its use may account for the increased prevalence of BP observed in PD patients without prior skin conditions. Our hypothesis is limited in that the patient's BP was not confirmed histologically during the exacerbation (although diagnostic histology had been done during his past BP episode). In addition, his mycophenolate mofetil had been discontinued before the episode, potentially making him more susceptible to BP recurrence. However, use of the Naranjo adverse drug reaction probability scale indicated a probable relationship between the patient's development of skin lesions and amantadine therapy.⁶

Commonly reported adverse effects of amantadine include gastrointestinal complaints, mood symptoms, and sleep disturbance.⁷ More adverse events, such as delusions, paranoia, corneal edema, hypertension, and urinary retention, have also been reported. A link between amantadine and BP has not been identified previously. To clarify whether amantadine contributes to the increased incidence of BP in PD patients, further exploration of the medication profiles of PD patients who develop BP is merited.

FIGURE 1. Bullous pemphigoid in a geriatric patient with PD and amantadine treatment. The patient provided written consent for use of these photographs for publication.

AQ1
AQ2

Given that amantadine is used off-label for several psychiatric indications, for example, for cognition in traumatic brain injury patients, antipsychotic-associated extrapyramidal symptoms, and fatigue in multiple sclerosis, an awareness of amantadine-associated BP is important for the psychiatrist who prescribes this medication.^{8–10} History of PD and the use of immunomodulation therapies need to be considered in cases of apparent amantadine-associated BP.

AUTHOR DISCLOSURE INFORMATION

The authors report no relevant financial relationships and no conflict of interest.

Sarah Hoffer, BMSc, MSc
BHSc (PA) candidate
McMaster University
Hamilton, Ontario
Canada

Ana Hategan, MD
Department of Psychiatry
and Behavioural Neurosciences
Division of Geriatric Psychiatry
Michael G. DeGroote School of Medicine
Faculty of Health Sciences
McMaster University
Hamilton, Ontario

Canada
ahategan@stjosham.on.ca

James A. Bourgeois, OD, MD
Department of Psychiatry
Baylor Scott & White Health
Central Texas Division
and Department of Psychiatry
Texas A&M University Health Science Center
College of Medicine
Texas A&M University
Temple, TX

REFERENCES

1. Hammers CM, Stanely JR. Mechanisms of disease: pemphigus and bullous pemphigoid. *Annu Rev Pathol*. 2016;11:175–197.
2. Stavropoulos PG, Soura E, Antoniou C. Drug-induced pemphigoid: a review of the literature. *J Eur Acad Dermatol Venereol*. 2014;28:1133–1140.
3. Schmidt E, Zillikens D. Pemphigoid diseases. *Lancet*. 2013;381:320–332.
4. Langan SM, Groves RW, West J. The relationship between neurological disease and bullous pemphigoid: a population-based case-control study. *J Invest Dermatol*. 2011;131:631–636.
5. Draper HM. Depressive disorder associated with mycophenolate mofetil. *Pharmacotherapy*. 2008;28:136–139.
6. Naranjo CA, Shear NH, Lanctôt KL. Advances in the diagnosis of adverse drug reactions. *J Clin Pharmacol*. 1992;32:897–904.
7. Rodriguez-Garcia A, Gonzalez-Godinez S, Macias-Rodriguez Y. Amantadine corneal toxicity: case report and review of the literature. *Int J Ophthalmic Pathol*. 2015;4:1–5 Available at: https://www.scitechnol.com/amantadine-corneal-toxicitycase-report-and-review-of-the-literature-SQ1o.php?article_id=3716. Accessed March 12, 2018.
8. Stelmaschuk S, Will MC, Meyers T. Amantadine to treat cognitive dysfunction in moderate to severe traumatic brain injury. *J Trauma Nurs*. 2015;22:194–203.
9. Werner F, Coveñas R. Pharmacological options in the treatment of antipsychotic-induced extrapyramidal symptoms. *J Cytol Histol*. 2016;7:416 Available at: <https://www.omicsonline.org/open-access/pharmacological-options-in-the-treatment-of-antipsychoticinducedextrapyramidal-symptoms-2157-7099-1000416.php?aid=74331>. Accessed March 18, 2018.
10. Santarnecchi E, Rossi S, Bartalini S, et al. Neurophysiological correlates of central fatigue in healthy subjects and multiple sclerosis patients before and after treatment with amantadine. *Neural Plast*. 2015;2015:1–9. Available at: <https://www.hindawi.com/journals/np/2015/616242/>. Accessed March 18, 2018.

AQ3

AUTHOR QUERIES

AUTHOR PLEASE ANSWER ALL QUERIES

AQ1 = Please check if authors name are correctly captured for given names (in red) and surnames (in blue) for indexing after publication.

AQ2 = Please check if the captured data in affiliation address are appropriate.

AQ3 = Please check and confirm if the captured page range for Ref. 10 is appropriate.

END OF AUTHOR QUERIES